Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K12 | Q12852 | 1/20 | 0.36 |
| ▸ | IDO1 | P14902 | 10/20 | 0.36 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.34 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.34 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.34 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.34 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.34 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.34 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10183168 | 0.87 | HCAR1 (0.40) | IDO1GPR119PSEN1PSEN2APH1B | |
| SCHEMBL10183285 | 0.86 | ALDH1A1 (0.46) | IDO1PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL10183257 | 0.84 | IDO1 (0.37) | IDO1ALDH1A1GAA | |
| SCHEMBL10234149 | 0.83 | ALDH1A1 (0.37) | MAP3K12IDO1GPR119PSEN1PSEN2 | |
| SCHEMBL10183166 | 0.80 | HCAR1 (0.47) | GPR119 | |
| SCHEMBL10183244 | 0.79 | IDO1 (0.35) | IDO1ALDH1A1MEN1HPGDKMT2A | |
| SCHEMBL10183230 | 0.77 | GLRA3 (0.35) | IDO1GAA | |
| SCHEMBL10183263 | 0.77 | GLRA3 (0.41) | IDO1ALDH1A1MEN1HPGDKMT2A | |
| SCHEMBL10183626 | 0.76 | EGFR (0.40) | IDO1ALDH1A1HPGDGAA | |
| SCHEMBL10183159 | 0.74 | JAK1 (0.35) | IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120040951-A1 | HETEROARYL COMPOUNDS USEFUL AS RAF KINASE INHIBITORS | SUNESIS PHARMACEUTICALS, INC. | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040951-A1 | HETEROARYL COMPOUNDS USEFUL AS RAF KINASE INHIBITORS | BRAF, RAF1, ARAF | MAP3K12 39/4885IDO1 3440/4885GPR119 2713/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.